Latest News - AbbVie
Top Corporates Hub
AbbVie
Stocks Slide as Focus Shifts to Iran Deal Hurdles: Markets Wrap
19.06.2026 15:34
(Bloomberg) -- Global stocks are ending a strong week on a cautious note as relief over an interim peace deal between the US and Iran gave way to a focus on the hurdles that remain to secure a lasting agreement.Most Read from BloombergRead the 14-Point Draft Memorandum Between the US and IranModi Warns of ‘Shortage of Trust’ Ahead of Trump MeetingTrump Blows Through His Iran Red Lines in Justifying Peace DealUS and Iran Delay Nuclear Talks as Lebanon Clashes WorsenUS Tells ASML It’s Concerned Ch
AbbVie: Immunology Cash Flow Funds Oncology Expansion
19.06.2026 09:51
AbbVie stock stays a buy on FDA approvals, strong R&D, and rising Venclexta revenue. Click here to read more on the ABBV stock.
AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
18.06.2026 11:13
AbbVie (NYSE:ABBV) reported positive Phase 3 results for a venetoclax-based combination in untreated chronic lymphocytic leukemia in less-fit patients. The company also received U.S. FDA approval for SKINVIVE by JUVÉDERM for reducing neck lines and improving neck appearance. AbbVie operates at the intersection of large-scale pharmaceuticals and medical aesthetics, with products that span immunology, oncology, neuroscience and cosmetic treatments. The latest data in chronic lymphocytic...
Abivax: Safety Signals Loom Ahead Of The NDA Submission
18.06.2026 06:53
ABIVAX plans NDA submission for obefazimod in Q4 2026, with Crohnâs disease Phase 2b data delayed to mid-2027. Learn why ABVX stock is a strong sell.
AbbVie Inc (NYSE:ABBV) Breakout Setup Combines Strong Technical Rating with High-Quality Consolidation Entry
17.06.2026 12:00
A technical breakout strategy combining strong uptrend stocks with tight consolidation patterns for low-risk entry points, using AbbVie (ABBV) as a key example.
AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73
13.06.2026 14:09
If you are wondering whether AbbVie at around US$227.73 is still offering fair value, the starting point is to understand what the current price actually reflects. The stock has inched up 0.2% over the past week and 9.2% over the last month, while the year to date return is slightly down 0.7% and the 1 year, 3 year and 5 year returns sit at 23.1%, 82.9% and 142.8% respectively. These moves have kept AbbVie on the radar as investors weigh long term performance against current pricing. Recent...
3 Stocks That Might Be Up To 39.8% Below Their Estimated Intrinsic Value
12.06.2026 11:38
Over the last 7 days, the United States market has dropped 2.4%, though it has risen by 22% over the past year, with earnings forecasted to grow by 18% annually. In this context, identifying stocks that might be trading below their estimated intrinsic value can present potential opportunities for investors looking to capitalize on undervalued assets.
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
12.06.2026 07:00
AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation.
Coastal Financial And 2 Additional Stocks Estimated To Be Priced Below Intrinsic Value
10.06.2026 17:37
Over the last 7 days, the United States market has dropped 3.3%, yet it remains up 22% over the past year with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying stocks that are potentially priced below their intrinsic value can offer opportunities for investors seeking long-term growth, such as Coastal Financial and two other noteworthy companies.
Final Trades: AbbVie, Devon Energy and the 2-Year and 10-Year Treasuries
10.06.2026 13:06
The Investment Committee give you their top stocks to watch for the second half.
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
10.06.2026 12:00
Allergan Aesthetics, an AbbVie company, today announced the release of What Consumers Really Want, the latest installment in The Aesthetics Evolution series. On the heels of The Hyaluronic Injectable Fillers Report, this report profiles today's aesthetics consumers, how their views on aesthetics are shaped and shifting, and what they expect from a personalized, end-to-end aesthetic experience.
3 Stocks Conceivably Trading At Discounts Of Up To 49.6%
10.06.2026 11:38
Over the last 7 days, the United States market has dropped 3.3%, yet it remains up by 22% over the past year, with earnings expected to grow by 17% annually in the coming years. In this fluctuating environment, identifying stocks that may be trading at a discount can offer investors opportunities to capitalize on potential value gains.
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
08.06.2026 17:38
Over the last 7 days, the United States market has dropped 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this environment, identifying stocks that may be priced below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
08.06.2026 12:00
AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentation
Getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick.
03.06.2026 07:30
The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.
Getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick.
03.06.2026 07:30
The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
03.06.2026 07:15
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.Dr. Beaver has held senior leadership positions at several...
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
03.06.2026 07:15
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.Dr. Beaver has held senior leadership positions at several...
AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO®
02.06.2026 14:42
AbbVie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. AbbVie Inc. (NYSE:ABBV) announced on May 29 authorization by the European Commission (EC) for an expanded label for VENCLYXTO® to include use in combination with acalabrutinib (with or without obinutuzumab), along with use in combination with ibrutinib to […]
The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains
02.06.2026 14:05
AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.